Abaxis supplies point of care blood analyzers to the medical market and the veterinarian market. Abaxis provides technology, tools and services that support best medical practices, enabling physicians and veterinarians to respond to the health needs of their clients at the point of care while operating economical and profitable practices. Abaxis is headquartered in northern California, USA, and conducts operations around the world.
Abaxis has filed 45 patents.
Analytical chemistry, Molecular biology, Mass spectrometry, Chromatography, Biochemistry methods
Analytical chemistry, Molecular biology, Mass spectrometry, Chromatography, Biochemistry methods
Latest Abaxis News
Jul 31, 2023
News provided by Share this article Share this article DUBLIN, July 31, 2023 /PRNewswire/ -- The "Global Diagnostic Substances - Industry Report" report has been added to ResearchAndMarkets.com's offering. The report offers a comprehensive analysis of the diagnostic substances market, covering key players and financial trends. With detailed information on the top 70 companies, including Abaxis Inc, Canon Medical Systems and Galderma Laboratorium, this report provides valuable insights into the diagnostic and healthcare industry. Key Highlights: Market Overview: The report provides an overview of the diagnostic substances market, focusing on areas such as diagnostics, diagnosis, substances, health, and healthcare. It includes financial trends analysis over the past four years, offering a comprehensive view of the industry. Company Analysis: Using the publisher's exclusive methodology, the report assesses the financial performance of the top 70 companies. It highlights 17 companies with a declining financial rating and 7 companies that have shown good sales growth. Market Analysis: The report offers a thorough 100-page market analysis, presenting the latest changes and trends in the global diagnostic substances market. It covers best trading partners, sales growth analysis, profit analysis, market size, and rankings. Tools for Busy Managers: The report equips busy managers with tools to monitor the financial welfare of their companies, rivals, or potential acquisitions. The reports help assess the attractiveness of acquisitions, gain a better understanding of the market, and identify sound companies for trading partnerships. The report is divided into two sections: an overall market analysis and a detailed company analysis. The market analysis includes best trading partners, sales growth analysis, profit analysis, market size, and rankings. The company analysis provides an in-depth assessment of the largest companies in the diagnostic substances industry, using the publisher's unique model and The Publisher's Chart to analyze financial performance. With the most up-to-date financial data, this report offers accurate insights into the diagnostic substances market. It serves as a valuable resource for industry professionals seeking to understand market trends, identify potential acquisitions, and benchmark their own financial performance. For more information about this report visit https://www.researchandmarkets.com/r/tv37m5 About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact:
Abaxis Frequently Asked Questions (FAQ)
When was Abaxis founded?
Abaxis was founded in 1989.
Where is Abaxis's headquarters?
Abaxis's headquarters is located at 3240 Whipple Road, Union City.
What is Abaxis's latest funding round?
Abaxis's latest funding round is Acq - P2P.
How much did Abaxis raise?
Abaxis raised a total of $7.37M.
Who are the investors of Abaxis?
Investors of Abaxis include Zoetis, Mayfair Capital Investment Management, Horizon Offshore and MedVenture Associates.
Who are Abaxis's competitors?
Competitors of Abaxis include Truvian, Theranos, BionX Medical Technologies, MSDx, Drew Scientific and 7 more.
Compare Abaxis to Competitors
Mercator MedSystems is a medical technology company that focuses on the treatment of peripheral artery disease. The company offers catheter-guided, microfluid injection systems for site-specific, non-systemic delivery of therapeutic agents directly across any blood vessel, providing efficient and targeted treatment for vascular diseases. The technology also finds application in the treatment of hypertension, oncology, and regenerative medicine. Mercator MedSystems was formerly known as EndoBionics. It was founded in 1999 and is based in Emeryville, California.
Pulse Metric designs, manufactures and markets products and services that transform a simple blood pressure reading into a powerful functional profile of the patients cardiovascular system, including cardiac output, vessel compliance, vascular resistance and left ventricular contractility. Within a minute of uploading a DynaPulse blood pressure waveform to the DynaPulse Analysis Center website, 17 hemodynamic parameters are calculated, displayed and trended, providing clinicians with numeric values profiling the hearts pumping performance, blood vessel elasticity and vascular resistance, against normative ranges.The company believes the simplicity of its methodology and the significance of the information provided to the physician will improve quality of care while reducing costs. Pulse Metric has been granted nine patents in support of its proprietary technology.
Lifepoint is a medical technology company developing rapid and cost effective, non-invasive, on-site diagnostic products. The Company has developed and will continue to develop patented, proprietary technologies utilizing saliva as a test specimen to provide blood equivalent diagnostic results without the need for blood or urine.
CardioDynamics was incorporated in 1993 and is committed to fundamentally changing drug management with ICG. The Company's primary product, the BioZ, uses proprietary Impedance Cardiography (ICG) technology to noninvasively assess a patient's hemodynamics, data which typically has been unavailable in the physician's office and available on a limited basis in the hospital only through a time-consuming, costly, and potentially dangerous invasive procedure called Pulmonary Artery Catheterization (PAC), or the Swan Ganz Catheter. Since the BioZ's ICG monitoring is noninvasive, it can be performed in outpatient areas such as physician offices, which have never before had access to hemodynamic information in treating heart failure, high blood pressure, pacemaker, and dialysis patients. In physician offices, BioZ monitoring can decrease long term costs of hypertension management through the use of appropriate drug therapies. The reduction of blood pressure results in a decrease of more costly cardiovascular conditions including heart failure, strokes, and heart attacks. In hospitals, BioZ monitoring on surgical or intensive care patients can decrease costs through the elimination of procedure risk, reduction of hospital stay, and minimization of hospital expenditures and personnel. BioZ monitoring can also provide valuable hemodynamic information in hospital areas where previously it has not been available, such as emergency departments, critical care, step-down units, and dialysis. In this new era of cost containment, healthcare payors and providers are demanding greater efficiency and cost-effectiveness without diminishing the quality of care. The BioZ's ICG monitoring systems provide a solution to meet this growing demand.
Kjaya is a company that received a SBIR Phase I grant for a project entitled: Semi-Autonomous Adaptive Neural and Genetic Segmentation of Medical Images. Their Phase I project will implement a physician-assisted, real-time adaptive system for the segmentation of anatomical structures in 3D medical image data. Medical image segmentation seeks to change the representation of an anatomical structure, making it more easily analyzed. Because of the extreme variability of these structures in biological systems, current idiosyncratic manual methods currently in use are tedious, time consuming, and error prone. Image segmentation cannot in general be programmatically solved. The proposed system is a Neural Network (NN) based adaptation of the individual data using parallel Graphics Processing Units (GPUs) and coupled with a Genetic Algorithm (GA) based adaptation across GPU cores. The system will build a diagnostically useful segmentation of the anatomical feature within seconds from an area of interest outlined by a physician using a Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scan. Fast growth in medical imaging overwhelms available diagnosticians. An intuitive and inexpensive system to quickly and accurately deliver diagnostic relevant segmentation of medical images offers tremendous commercial value. Currently, each scan requires approximately 50 minutes of manual preparation. The diagnosis and treatment of an estimated 20 percent of diseases benefit from medical imaging. Newer scanning technologies have increased in resolution, but such techniques have not made segmenting easier or faster. The proposed method will enable more diagnostics to be done with the quality controlled directly by physicians.
Amsino International focuses on the development, manufacturing, and marketing of medical devices within the healthcare sector. The company offers a range of products including systems for medication delivery, enteral feeding, respiratory therapy, urological care, as well as sterile water and saline solutions. Amsino's products cater to the needs of healthcare providers in various medical settings. It was founded in 1993 and is based in Pomona, California.